Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Up 15.2% – Should You Buy?

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) shares traded up 15.2% during mid-day trading on Thursday . The company traded as high as $21.50 and last traded at $22.4270. Approximately 2,884,457 shares changed hands during trading, a decline of 5% from the average session volume of 3,051,465 shares. The stock had previously closed at $19.46.

Analysts Set New Price Targets

A number of research analysts have recently commented on the stock. Wolfe Research upgraded shares of Sarepta Therapeutics from a “peer perform” rating to an “outperform” rating and set a $27.00 price target on the stock in a report on Thursday, July 9th. Wall Street Zen cut shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. HC Wainwright reaffirmed a “buy” rating on shares of Sarepta Therapeutics in a research report on Tuesday, July 28th. Weiss Ratings downgraded shares of Sarepta Therapeutics from a “sell (d)” rating to a “sell (e+)” rating in a research note on Wednesday, August 19th. Finally, Zacks Research upgraded Sarepta Therapeutics from a “strong sell” rating to a “hold” rating in a report on Wednesday, August 12th. Nine equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and five have given a Sell rating to the company. Based on data from MarketBeat.com, Sarepta Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $25.06.

Sarepta Therapeutics Price Performance

The firm has a 50-day simple moving average of $17.73 and a 200-day simple moving average of $18.32. The firm has a market cap of $2.20 billion, a P/E ratio of -7.19, a PEG ratio of 0.32 and a beta of 0.23. The company has a current ratio of 4.42, a quick ratio of 2.62 and a debt-to-equity ratio of 0.55.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $0.64 earnings per share for the quarter, topping analysts’ consensus estimates of $0.22 by $0.42. Sarepta Therapeutics had a negative return on equity of 1.60% and a negative net margin of 13.48%.The firm had revenue of $401.25 million during the quarter, compared to analysts’ expectations of $366.39 million. During the same period in the prior year, the business posted $2.02 EPS. The firm’s quarterly revenue was down 34.3% on a year-over-year basis. As a group, analysts forecast that Sarepta Therapeutics, Inc. will post 3.43 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. PNC Financial Services Group Inc. increased its position in shares of Sarepta Therapeutics by 7.8% during the first quarter. PNC Financial Services Group Inc. now owns 8,751 shares of the biotechnology company’s stock worth $190,000 after purchasing an additional 636 shares in the last quarter. Thrivent Financial for Lutherans boosted its position in shares of Sarepta Therapeutics by 3.3% in the 2nd quarter. Thrivent Financial for Lutherans now owns 23,140 shares of the biotechnology company’s stock worth $396,000 after purchasing an additional 744 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Sarepta Therapeutics by 1.8% during the 3rd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,208 shares of the biotechnology company’s stock worth $829,000 after buying an additional 758 shares during the last quarter. Larson Financial Group LLC grew its stake in Sarepta Therapeutics by 82.5% during the 4th quarter. Larson Financial Group LLC now owns 1,882 shares of the biotechnology company’s stock worth $41,000 after buying an additional 851 shares during the last quarter. Finally, Public Employees Retirement System of Ohio increased its position in Sarepta Therapeutics by 3.1% during the 1st quarter. Public Employees Retirement System of Ohio now owns 28,787 shares of the biotechnology company’s stock valued at $626,000 after buying an additional 875 shares in the last quarter. Institutional investors own 86.68% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.